Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Eur J Cancer ; 50(13): 2289-97, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24997493

RESUMO

BACKGROUND: Pulmonary metastasectomy when possible has become therapeutic standard in soft tissue sarcoma patients. However, published reports frequently describe mixed series of patients with bone or soft tissue sarcoma. We report the outcome of 46 soft tissue sarcoma (STS) patients who underwent pulmonary metastasectomy (PM). METHODS: This current analysis includes retrospective survival data from 46 consecutive STS patients with pulmonary metastases who underwent PM at the Medical University of Vienna between January 2003 and December 2013. RESULTS: In total 72 pulmonary metastasectomies were performed. 322 metastatic nodules were resected with a median number of four nodules per intervention and the R0 resection rate was 97.2%. The postoperative complication rate as documented was low. Median follow-up (mFU) was 31.8 months (range 3.7-127.4). Median overall survival as calculated from first detection of metastatic disease was 47.1 months (95% confidence interval (CI)=36.2-58.1 months) and 45.3 months (95% CI=33.3-57.4 months) when calculated from first PM until death or last follow-up (n=46). Five-year overall survival calculated from primary diagnosis was 62% and 32% when estimated from first PM. Previous disease free interval (DFI) as calculated from date of surgery of the primary tumour until the date of diagnosis of lung metastasis was 12.2 months (range 0-140.1 months). Median relapse-free survival (mRFS) after first PM to the date of recurrence of lung metastasis, death or last follow-up was 13.4 months (95% CI=3-23.8 months). CONCLUSION: Median overall survival in this selected patient cohort is 45.3 months. Despite the lack of prospective randomised controlled trials, PM is a reasonable treatment strategy in selected patients.


Assuntos
Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/cirurgia , Metastasectomia/métodos , Sarcoma/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Áustria , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Sarcoma/patologia , Taxa de Sobrevida , Resultado do Tratamento
2.
Technol Cancer Res Treat ; 6(6): 655-60, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17994797

RESUMO

The effect of preoperative radio chemotherapy on lymphatic drainage and intraoperative gamma probe-guided sentinel lymph node detection has yet not been investigated. In this study, we study 13 patients with SCC. Sentinel lymph node (SLN) imaging of the patients was performed using SPECT-CT. Special care was taken to use identical injection sites for both studies. Imaging comprised planar and SPECT, iterative reconstruction and were viewed with the co-registered CT image. The results were validated by comparison with the histological results of intraoperative gamma probe detection and histology of the completed neck dissection. Identical SLNs were found in 6/13 patients. In 2/13 cases SLN biopsies were false-negative. In 4/13 patients preoperative SLN imaging identified more/additional nodes than the initial imaging, whereas fewer nodes were seen in 3/13 patients. Neither the primary tumor site nor the TNM stage was predictive for changes in the lymphatic drainage pattern. No constant effect of irradiation could be demonstrated. Preoperative radio chemotherapy has an unpredictable influence on the lymphatic drainage pattern in HNSCC. Consequently, the intraoperative gamma probe-guided sentinel lymph node detection after radio chemotherapy does not reveal the SLN of carcinogenesis. Thus, we advise fused functional/anatomical imaging (SPECT-CT) before and after radiochemotherapy if the SLN concept is utilized in HNSCC.


Assuntos
Carcinoma de Células Escamosas/terapia , Neoplasias de Cabeça e Pescoço/terapia , Linfonodos/efeitos dos fármacos , Linfonodos/efeitos da radiação , Terapia Neoadjuvante/efeitos adversos , Biópsia de Linfonodo Sentinela , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/patologia , Quimioterapia Adjuvante , Reações Falso-Negativas , Feminino , Neoplasias de Cabeça e Pescoço/patologia , Humanos , Metástase Linfática/diagnóstico , Masculino , Pessoa de Meia-Idade , Radioterapia Adjuvante , Tomografia Computadorizada de Emissão de Fóton Único
3.
Z Rheumatol ; 65(8): 681-7, 2006 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-17106667

RESUMO

Whole-body MR tomography at 3 T is moving steadily from research into routine clinical practice. The most important advantage of high-field MRI is the higher signal to noise ratio, which allows acquisitions in the musculo-skeletal system with higher resolution within the same scan time. The imaging of small joints, the visualization of labral anatomy and pathology in the shoulder and hip joints, as well as cartilage imaging will benefit from higher resolution protocols. In addition to improved morphological imaging of articular cartilage, the higher sensitivity of 3 T allows the clinical use of advanced MR techniques of cartilage such as T1 and T2 mapping, diffusion and sodium imaging. The improved spectral resolution with the higher field may improve metabolic imaging of tumors of the skeleton and soft tissues.


Assuntos
Artrite Reumatoide/diagnóstico , Processamento de Imagem Assistida por Computador/métodos , Imageamento Tridimensional/métodos , Articulações/patologia , Imageamento por Ressonância Magnética/métodos , Imagem Corporal Total/métodos , Cartilagem Articular/patologia , Meios de Contraste/administração & dosagem , Imagem de Difusão por Ressonância Magnética/métodos , Articulação do Quadril/patologia , Humanos , Aumento da Imagem/métodos , Espectroscopia de Ressonância Magnética/métodos , Sensibilidade e Especificidade , Articulação do Ombro/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA